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Background: Borderline personality disorder (BPD) is associated with a high socioeconomic burden. Although a
number of evidence-based treatments for BPD are currently available, they are not widely disseminated; furthermore,
there is a need for more research concerning their efficacy and cost-effectiveness. Such knowledge promises to lead to
more efficient use of resources, which will facilitate the effective dissemination of these costly treatments. This study
focuses on the efficacy and cost-effectiveness of Mentalization-Based Treatment (MBT), a manualized treatment for
patients with BPD. Studies to date have either investigated MBT in a day hospitalization setting (MBT-DH) or MBT
offered in an intensive outpatient setting (MBT-IOP). No trial has compared the efficacy and cost-effectiveness of these
MBT programmes. As both interventions differ considerably in terms of intensity of treatment, and thus potentially in
terms of efficacy and cost-effectiveness, there is a need for comparative trials. This study therefore sets out to
investigate the efficacy and cost-effectiveness of MBT-DH versus MBT-IOP in patients with BPD. A secondary aim is to
investigate the association between baseline measures and outcome, which might improve treatment selection and
thus optimize efficacy and cost-effectiveness.
Methods/Design: A multicentre randomized controlled trial comparing MBT-DH versus MBT-IOP in severe BPD
patients. Patients are screened for BPD using the Structured Clinical Interview for DSM-IV Axis II Personality Disorders,
and are assessed before randomization, at the start of treatment and 6, 12, 18, 24, 30 and 36 months after the start of
treatment. Patients who refuse to participate will be offered care as usual in the same treatment centre. The primary
outcome measure is symptom severity as measured by the Brief Symptom Inventory. Secondary outcome measures
include parasuicidal behaviour, depression, substance use, social, interpersonal, and personality functioning, attachment,
mentalizing capacities, and quality of life. All analyses will be conducted based on the intention-to-treat principle.
Cost-effectiveness will be calculated based on costs per quality-adjusted life-year.
Discussion: This multisite randomized trial will provide data to refine criteria for treatment selection for severe BPD
patients and promises to optimize (cost-)effectiveness of the treatment of BPD patients.
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Treatment dosageBackground
Borderline personality disorder (BPD) is among the most
prevalent mental disorders [1,2]. The inability to menta-
lize, particularly in emotional interactions, is considered
to be one of the key problems in BPD [3]. Mentalizing re-
fers to “the mental process by which an individual impli-
citly and explicitly interprets the actions of himself and
others as meaningful on the basis of intentional mental
states such as personal desires, needs, feelings, beliefs, and
reasons” ([3], p21). Patients with BPD typically suffer from
severe impairments in this capacity, resulting in emotional
instability, impulsive behaviour, and vulnerability in inter-
personal and social interactions [3]. Severe BPD patients
almost invariably show high psychiatric comorbidity, par-
ticularly depression, anxiety or eating disorders, substance
abuse [4-6], various other personality disorders [4,7-12]
and high levels of acting-out (e.g., suicidality) [13]. BPD is
also associated with seriously impaired quality of life [1]
and a high economic burden of disease [14]. Lifetime risk
for completed suicide associated with BPD is up to 10%
[13]. Together, these findings emphasize the need for the
development and dissemination of effective treatments for
this severe disorder.
Psychotherapy is considered to be the treatment of
choice for BPD patients [1,2]. Several guidelines [2,15-19]
recommend outpatient psychotherapy such as Transfer-
ence Focused Psychotherapy [20,21], Dialectical Behaviour
Therapy [22], Schema-Focused Therapy [23], and
Mentalization-Based Treatment (MBT) [3] for BPD.
This study focuses on MBT. MBT, which was devel-
oped by Bateman and Fonagy [3,24,25] in the United
Kingdom, is a promising evidence-based treatment that
has its roots in attachment theory. The aim of MBT is
to help patients develop an increasingly robust mentaliz-
ing process within everyday interpersonal interactions. A
day hospital MBT (MBT-DH) [26-28] and an intensive
outpatient MBT (MBT-IOP) [29] programme have been
developed and empirically evaluated. Although the pro-
grammes are similar in length (18 months, consisting of a
12 month treatment and 6 months maintenance phase),
they differ markedly in intensity, particularly with regard
to the role of group therapy. The treatment phase of
MBT-DH consists of a five days per week day hospital
treatment that comprises daily group psychotherapy,
weekly individual psychotherapy, individual crisis manage-
ment from a mentalizing perspective, art therapy twice a
week, mentalizing cognitive therapy, and writing therapy.MBT-IOP consists of group psychotherapy once a week,
weekly individual psychotherapy, and individual crisis
management from a mentalizing perspective.
Both treatment programmes have been empirically
evaluated in randomized controlled trials (RCTs), but
none of these trials has directly compared MBT-IOP and
MBT-DH. In a first trial [26-28], 38 BPD patients were
randomized to either MBT-DH or treatment as usual
(TAU). TAU consisted of standard treatment offered in
the UK in general psychiatric services and consisted of
(a) regular psychiatric review with a senior psychiatrist
when necessary (on average twice a month), (b) inpatient
admission when necessary, with discharge to nonpsy-
choanalytic psychiatric partial hospitalization focusing
on problem solving, followed by (c) outpatient and com-
munity follow-up as standard aftercare [26]. Results after
18 months showed that MBT-DH was superior to TAU
on all major outcome variables; that is, depressive symp-
toms, suicide attempts and self-harm, number of inpatient
days, and social and interpersonal functioning. These re-
sults were maintained during an additional 18-month
follow-up period [30]. At 5-year follow-up after discharge,
the MBT-DH group showed further improvements on sui-
cidality, diagnostic status, service use, use of medication,
global functioning scores above 60 (Global Assessment of
Functional Scale; GAF) and vocational status [28]. For ex-
ample, whereas 74% of the patients in the TAU condition
made at least one suicide attempt, only 23% in the MBT-
DH group did so. At the end of the follow-up period, 13%
of the MBT-DH patients met diagnostic criteria for BPD,
compared with 87% of the TAU group. This trial also
yielded data concerning health costs. Before treatment,
the total health-related costs for the MBT-DH group
($44,947) and the TAU group ($52,563) were comparable;
after 18 months of treatment, costs were reduced
to $27,303 in MBT-DH and $30,976 in TAU. During the
18-month follow-up, costs further diminished sharply in
the MBT group. At 18-month follow-up, the total health-
related costs in the MBT-DH group were one-fifth of costs
for patients in the TAU condition ($3,183 for MBT-DH
versus $15,490 for TAU) [30]. However, this study did not
include a formal cost-effectiveness analysis.
Two other studies provide further support for the effi-
cacy of MBT-DH. An RCT in Denmark investigated the
efficacy of MBT-DH compared with a less intensive man-
ualized supportive group therapy combined with psychoe-
ducation and medication treatment in patients diagnosed
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cated to MBT-DH and 27 patients to the specialist com-
bined treatment. Results showed that both MBT-DH and
the less intensive supportive group therapy led to signifi-
cant improvements on a variety of psychological and inter-
personal measures, e.g., general functioning, depression,
social functioning and number of diagnostic criteria for
BPD [32], with moderate to large effect sizes (d = 0.5 to
2.1). MBT-DH was superior only on therapist-rated
GAF [31] after two years of treatment. No follow-up or
cost-effectiveness data are yet available from this trial. A
naturalistic effectiveness study in the Netherlands [33]
investigated the effectiveness of 18-month, manualized
MBT-DH in 45 patients with severe BPD and high co-
morbidity in terms of Axis I and Axis II disorders. Re-
sults showed significant improvements in symptomatic
distress, social and interpersonal functioning, and person-
ality pathology and functioning; with moderate to large ef-
fect sizes (d = 0.7 to 1.7). In addition, the Netherlands
study showed that care consumption reduced significantly
during and after treatment. However, the lack of a control
group limits the ability to draw conclusions about the ef-
fectiveness of MBT-DH.
Finally, with regard to MBT-IOP, an RCT [29] showed
that this less intensive treatment programme was more ef-
fective than structured clinical management in an RCT
with 134 BPD patients. Substantial improvements were
observed in both treatment conditions across all outcome
variables. However, the MBT-IOP group showed a steeper
decline on both self-reported and clinically significant
problems, including suicide attempts and hospitalization.
Cost analyses were not included in this trial.
As noted, a ‘head to head’ cost-effectiveness trial directly
comparing MBT-IOP with MBT-DH has not yet been con-
ducted. An indirect comparison between MBT-DH and
MBT-IOP based on the UK trials [26,29] is hampered by
pretreatment patient differences; with the patients in the
MBT-DH trial evidencing substantially higher levels of
symptomatic distress, depression and interpersonal prob-
lems (between-group difference d = 0.7 to 0.8). This
stresses the need for a comparative trial that also compares
the cost-effectiveness of MBT-DH and MBT-IOP, particu-
larly as MBT-DH may be approximately twice as expensive
as MBT-IOP [34].
A further reason why a direct comparison trial is cur-
rently indicated relates to the current shift in psychother-
apy research from the identification of effective treatments
to the search for variables that might predict treatment re-
sponse, with the hope of better matching patients to spe-
cific treatments (i.e., to identify “what works for whom”)
[35]. Various patient characteristics have been proposed
and studied as predictors of treatment outcome with
MBT. Furthermore, changes in mentalizing capacities and
attachment have been proposed as mechanisms of changein MBT. Little is known, however, about predictors of
treatment and mechanisms of change in the treatment of
BPD patients, and with MBT in particular. Bateman and
Fonagy [36] found pretreatment severity, defined in terms
of the number of personality disorders, to be a possible in-
dicator for more favorable treatment outcomes in special-
ist treatment. No study to date has investigated purported
mechanisms of change in MBT. The current trial there-
fore aims to identify potential predictors of response in
both treatments with the aim to facilitate treatment selec-
tion and optimize (cost)-effectiveness. Furthermore, it
aims to investigate mechanisms of change in both treat-
ment programmes.
Research aims and hypotheses
The primary aim of the present study is to investigate the
efficacy of MBT-DH in comparison to MBT-IOP. The pri-
mary outcome measure is symptom severity as measured
by the Brief Symptom Inventory [37,38]. Secondary out-
come measures include parasuicidal behaviour, depression,
substance use, social, interpersonal and personality func-
tioning, attachment, mentalizing capacities, and quality of
life. We expect that patients in both MBT-DH and MBT-
IOP will improve, but that MBT-DH will outperform
MBT-IOP because of its higher dosage.
A secondary aim is to investigate the cost-effectiveness
of both treatments based on costs per quality-adjusted
life-year (QALY). We expect that the greater benefits of
MBT-DH will not outweigh the lower costs of MBT-
IOP. Therefore, we expect MBT-IOP to be more cost-
effective than MBT-DH.
Third, we aim to explore the role of pretreatment vari-
ables in predicting treatment outcome in both interven-
tions, with the aim to optimize treatment selection and
thus (cost-)effectiveness.
Finally, this study aims to investigate whether MBT is
associated with changes in mentalizing capacities and




This study is a multisite RCT comparing the efficacy
and cost-effectiveness of MBT-DH versus MBT-IOP in
the treatment of BPD (see Figure 1). Patients are ran-
domly allocated to either MBT-DH or MBT-IOP and
assessed before randomization, before start of treatment
and subsequently every 6 months up to 36 months after
start of treatment.
Initially, five mental health care centres specializing in the
treatment of BPD agreed to participate in this study (NPI,
Amsterdam; GGZinGeest, Amsterdam; De Viersprong,
location Bergen op Zoom; De Viersprong, location
Amsterdam; and Lentis, Groningen). NPI, GGZinGeest,
Figure 1 Patient flow chart.
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to provide two MBT-DH and two MBT-IOP groups. De
Viersprong location Amsterdam and Lentis both agreed
to provide one MBT-DH group and one MBT-IOP
group. Before the actual start of the study, one of the
participating centres (GGZinGeest) could no longer
offer MBT-DH because of a reorganization of its clinical
services, and accordingly withdrew from participating
in the study. Due to implementation problems, NPI re-
duced its capacity to one MBT-IOP group and one
MBT-DH group. De Viersprong location Amsterdam,
however, has been able to expand its capacity to two
MBT-DH groups and two MBT-IOP groups. Overall,
NPI, De Viersprong (locations Bergen op Zoom and
Amsterdam) and Lentis will provide a total of 6 MBT-
DH and 6 MBT-IOP groups. The recruitment of pa-
tients began in January 2012 and ended in June 2014.Ethics
The Medical Ethical Committee of Erasmus Medical
Center, Rotterdam, the Netherlands, has approved this
study, registered under NL38571.078.12.
Participants and eligibility criteria
The target group consists of adult patients (18+) with
BPD, consecutively referred for treatment by general prac-
titioners, mental health care institutions, private practices
and general hospitals.
Inclusion criteria for MBT treatment and for this study
Inclusion criteria are (a) a BPD diagnosis as assessed
using the Structured Clinical Interview for DSM-IV Axis
II Personality Disorders (SCID-II) [39], (b) 18 years or
older, (c) adequate mastery of the Dutch language and (d)
travel time to the MBT setting less than 1 hour.
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Exclusion criteria for MBT are kept to a minimum be-
cause the treatment aims to reach a broad population of
BPD patients. In this study, only patients with (a) a diag-
nosis of autism spectrum disorders, chronic psychotic
disorder or organic brain disorder that interferes signifi-
cantly with the ability to mentalize; (b) intellectual im-
pairment (IQ <80 as measured by the Wechsler Adult
Intelligent Scale–III) [40]; or (c) a diagnosis of antisocial
personality disorder in combination with a history of se-
vere physical violence are excluded. In addition, patients
who have had a stable job for a period of at least 2 years
for a minimum of 15 hours a week, and/or are caregivers
with main responsibility for children under 4 years of
age, are allowed to participate in the randomized study
at their own choice. Because of ethical reasons (i.e.
randomization to MBT-DH cannot be combined with a
job or being the main carer for children because of the
fixed time commitment involved), these patients were
not seen as refusers, and were given the option to enter
MBT-IOP directly.
Procedure
All patients referred to one of the mental health care
centres are invited for a standard intake interview, which
includes standardized assessment by means of the Struc-
tured Clinical Interview for DSM-IV Axis I disorders
(SCID-I) [41] and SCID-II [39]. All patients eligible for
MBT treatment (with a BPD diagnosis and aged ≥18 years)
are given both written and verbal information about the
study. Eligible patients are given 1 week to consider par-
ticipation in the trial. Patients who are willing to partici-
pate in the study are asked to sign an informed consent
sheet and complete the baseline assessment. Next, they
are randomized to either MBT-DH or MBT-IOP by an in-
dependent researcher using a computerized 1:1 algorithm.
Patients are informed about their treatment allocation and
placed on a waiting list. One week prior to start of the
main treatment phase, and subsequently at 6-months in-
tervals up to 36 months after the start of treatment, pa-
tients complete an assessment battery as described below.
Patients who are excluded from the trial on the basis of
exclusion criteria, or who refuse to participate in the trial,
are ideally assigned to an alternative evidence-based treat-
ment. Excluded and refusing patients are asked to
complete the baseline assessment only, for which they sign
a separate informed consent form. At 18 and 36 months,
the SCID-I and SCID-II are re-administered by MSc-level
psychologists. Extensive efforts are being made to collect
data at the follow-up time points by means of an out-
reaching approach towards patients: patients are contacted
by telephone, e-mail and letters (with reminders as neces-
sary) to motivate them to attend assessments, and home
visits are made if necessary.Treatments
MBT was developed by Fonagy and Bateman in the
United Kingdom [3,24,25,42]. The term mentalizing
refers to the ability to attend to mental states in our-
selves and in others as we attempt to understand our
own actions and the actions of others on the basis of
intentional mental states. The aim of MBT as a ther-
apy is to help patients develop an increasingly robust
mentalizing process within the context of interper-
sonal interactions. Treatment begins with MBT-I, an
introductory phase with psychoeducational elements.
This is followed by a combination of individual and
group therapy.
MBT works through continuously helping the pa-
tient to maintain or re-establish a mentalizing process
while simultaneously stimulating the attachment sys-
tem by balancing the level of optimal arousal. With a
main focus on current rather than past experience, pa-
tients are encouraged to explore the mental states of
themselves and others, to become curious about alter-
native perspectives, to find out more about how they
think and feel about themselves and how this influences
their behaviour, and how distortions in understanding
themselves and others lead to problems in interpersonal
functioning. The exploration and identification of emo-
tions within multiple contexts, particularly interper-
sonal contexts, promotes the development of secondary
representations to primary affective experiences. This
enhances affect regulation and the development of a co-
herent sense of self. These elements form key compo-
nents of mentalizing capacity. In this manner, the work
in therapy addresses BPD patients' difficulties with
affect, impulse regulation and interpersonal functioning.
Destructive behaviour, which from an MBT perspective
is understood as an attempt to maintain a sense of sta-
bility and manage incomprehensible feelings in the absence
of a mentalizing capacity, is reduced as a consequence of
the development of this capacity. Another important focus
lies in generalizing improvements in daily life to wider
social functioning. Thus, by means of improving pa-
tients’ mentalizing capacity, several domains of func-
tioning are addressed.
Both MBT-DH and MBT-IOP have five general treat-
ment goals: (1) engagement in therapy; (2) reduction of
psychiatric symptoms, particularly depression and anx-
iety; (3) reduction of self-damaging, threatening or sui-
cidal behaviour; (4) improved social and interpersonal
functioning; and (5) stimulation of appropriate use of
general mental health services (including prevention of
reliance on prolonged hospital stays). Goals are person-
alized and linked to the components of the programme.
Both MBT programmes are divided into three phases:
(1) pretreatment, (2) main treatment, and (3) follow-up
treatment [3,24,25,42].
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Patients enter the pretreatment programme until a place
becomes available in the treatment to which each patient
has been randomized (MBT-DH or MBT-IOP). For both
MBT-DH and MBT-IOP the pretreatment programme
focuses on engaging the patients in treatment and crisis
management. It consists of an introductory course to
MBT (MBT-I), and biweekly individual sessions with crisis
planning as focus. MBT-I is an explicit mentalizing group
with a psychoeducational element, which is considered an
important part of the programme. The programme con-
sists of 12 highly structured sessions that stimulate pa-
tients to consider the overall process of mentalizing and
its relation to their problems, and how these problems will
be addressed in MBT [25,42].
Main treatment
MBT-DH MBT-DH is an intensive, manualized treat-
ment for patients with BPD. It has been described in de-
tail elsewhere [3,33]. Briefly, MBT-DH consists of a
highly structured day hospitalization programme with a
maximum duration of 18 months, covering five days per
week. MBT-DH consists of the following components:
daily group psychotherapy, weekly sessions of individual
psychotherapy, individual crisis planning on indication
(average: weekly for 3 months and from then on lower
in frequency), art therapy twice a week, mentalizing cog-
nitive group therapy, and writing therapy. Each week’s
programme is ended with a social hour and a commu-
nity meeting. Patients in the MBT-DH programme can
also consult a psychiatrist upon request and medication
is prescribed following American Psychiatric Association
(APA) guidelines [15].
MBT-IOP The main treatment phase in MBT-IOP con-
sists of group psychotherapy twice a week, weekly ses-
sions of individual psychotherapy, and individual crisis
management on indication (average: weekly for 3 months
and from then on lower in frequency). Patients can also
consult a psychiatrist upon request and medication is
prescribed following APA guidelines.
Follow-up treatment
For patients in either treatment condition, the final phase
of the programme offers individually tailored stepped-
down care aiming at relapse prevention, maintaining and
further enhancing the gains made in mentalizing capacity,
and stimulating further rehabilitative change and reinte-
gration into society.
Therapists
Both the MBT-DH and MBT-IOP teams consist of thera-
pists with broadly ranging level of experience, background,
and educational level. All therapists involved in the studyare certified psychologists, psychotherapists, psychiatrists,
nurses or art therapists. All clinicians who are involved in
the study have successfully completed a certified MBT
basic course, after which they receive continuous supervi-
sion in working with the MBT model.
Treatment adherence
One of the authors, D. L. Bales, trained by Anthony
Bateman, was involved in the implementation and moni-
toring of MBT at the different treatment sites. Adherence
to the MBT treatment model is monitored in several ways.
First, adherence in daily practice is monitored by means of
reflections after each group therapy session, in which ther-
apists are continuously stimulated to reflect on their ad-
herence to the treatment model. Specifically, therapists are
asked to reflect on whether their interventions have en-
hanced mentalizing which interventions have not achieved
this, and what alternative interventions might have been
more successful. Second, within both the MBT-DH and
the MBT-IOP programme, biweekly team supervision fo-
cuses on review of case material to increase therapists’
comprehension of mentalizing theory and their compe-
tency in working with the principles of MBT and the
spectrum of mentalizing interventions. Third, we will rate
the adherence to the model of both group and individual
sessions using videotaped sessions. Based on the videos,
raters trained in the use of the Adherence and Compe-
tence Scale [43] will measure therapist adherence.
Measurements
Demographic variables
At baseline, participants complete questions concerning
demographic variables such as their marital status, living
situation, religion, level of education, current job and
working situation, and questions concerning the main
earner in the family (relationship to the patient, annual
income, occupation and source of income).
Trauma
The prevalence of trauma in childhood is measured by
means of a Dutch translation of the short form of the
Childhood Trauma Questionnaire (CTQ) [44]. The CTQ
is administered only at the start of treatment (T1). The
CTQ is a retrospective, self-report questionnaire that mea-
sures five categories of childhood trauma experience, in-
cluding emotional, physical and sexual abuse as well as
emotional and physical neglect. Each subscale is measured
in 5 items rated on a 5-point Likert scale: (1) never true,
(2) rarely true, (3) sometimes true, (4) often true, and (5)
very often true. Each subscale score ranges from 5 (no his-
tory of abuse or neglect) to 25 (very extreme history of
abuse and neglect). Cutoff scores are defined for none (or
minimal) to low, low to moderate, moderate to severe and
severe to extreme exposure. Moderate to severe cutoff
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tory of childhood trauma in a specific category. Cutoff
scores are 13 or higher for emotional abuse, 10 or higher
for physical abuse, 8 or higher for sexual abuse, 15 or
higher for emotional neglect, and 10 or higher for physical
neglect. Research has shown good psychometric proper-
ties for both the original CTQ version [44,45] and the
Dutch translation [46].
Primary outcome measure
Symptom severity General psychopathological symp-
toms are assessed with the Dutch version of the Brief
Symptom Inventory (BSI) [37,38]. The BSI is the short
version of the Symptom Checklist-90. It consists of 53
items covering nine symptom dimensions (somatization,
obsession-compulsion, interpersonal sensitivity, depres-
sion, anxiety, hostility, phobic anxiety, paranoid ideation
and psychoticism) and yields three global indices of dis-
tress: Positive Symptom Distress Index, Positive Symp-
tom Total, and Global Severity Index (GSI). Possible GSI
scores range from 0 to 4, with higher scores indicating a
higher level of psychological and emotional distress. Re-
spondents have to rate each item (e.g., “your feelings are
easily hurt”) on a five-point scale ranging from 0 (not at
all) to 4 (extremely), representing the intensity of distress
relating to each item during the past 7 days. The reliability
of the Dutch version of the BSI is good (Cronbach’s α ran-
ging from .71 to .88, test-retest reliability ranging from
r = .71 to .89). These values are comparable to the original
BSI version of Derogatis [38].
Secondary outcome measures
Parasuicidal behaviour Suicide and self-harm are
assessed with the Suicide and Self-Harm Inventory (SSHI)
[3]. The SSHI is a semi-structured interview assessing (a)
the frequency and severity of suicidal acts in the past
6 months, and (b) the frequency and severity of acts of
self-mutilation in the past 6 months. Multiple acts of self-
mutilation over a short period of time – for example, fren-
zied self-cutting – are counted as a single act.
Symptomatic distress Symptomatic distress is assessed
with the Beck Depression Inventory (BDI-I), and the
Measurements in the Addictions for Triage and Evalu-
ation (MATE).
The BDI-I is used to assess depressive symptoms [47,48].
The BDI-I is a self-report instrument that consists of 21
questions concerning depressive symptoms during the
past week. Each question has a set of four possible an-
swers, ranging in intensity from 0 to 3, for example, “I
don’t feel sad” (0) to “I feel so sad or unhappy that I
cannot bear it anymore” (3). The total scores for the in-
strument are categorized: 0–9 no depression, 10–18 mild-
moderate depression, 19–29 moderate-severe depression,30–63 severe depression. The BDI has shown good psy-
chometric qualities for both the original [47,48] and the
Dutch version [49-51].
The substance use section of MATE 2.0 [52] is used to
assess substance abuse and dependency. This section,
which is designed as an interview, asks about the use of
psychoactive substances in the past month and during
the lifetime. The interviewer in this study was an MSc-
level psychologist. The interrater reliability of this instru-
ment ranges between 0.75 and 0.92 [53].
Attachment and mentalizing capacities Attachment is
assessed with the Experiences in Close Relationships (ECR)
questionnaire. Mentalizing capacities are measured by the
Reflective Functioning Questionnaire (RFQ), the Reading
the Mind in the Eyes Test (RMET), and the FaceMorph
task.
A Dutch translation of the Experiences in Close Rela-
tionships questionnaire (ECR) [54,55] measures adult at-
tachment in romantic relationships. It contains two
subscales: Anxiety (sample item: “I worry about being
abandoned”) and Avoidance (“I feel very uncomfortable
when my partner wants to have a close connection to
me”) both consisting of 18 items. Individuals are asked
to rate each statement on a 7-point Likert scale ranging
from 1 (disagree strongly) to 7 (agree strongly). The
Dutch version of the ECR was found to be a valid meas-
ure with good internal and external validity [55].
The RFQ assesses reflective functioning (a close proxy
for mentalizing capacities) with 57 items that are rated
on a 7-point scale (1 = strongly disagree to 7 = strongly
agree). An example item is “People's thoughts are a mys-
tery to me." As this measure is still under development,
no psychometric data are yet available.
The Reading the Mind in the Eyes Test (RMET) [56]
was developed as a measure of capacities in adults. Pa-
tients are shown photographs of 36 pairs of eyes, and
have to match the eyes in each picture with one of four
written expressions describing different emotions. In this
study, a Dutch version of the RMET is being used [57].
The FaceMorph task is an experimental computerized
task assessing capacities based on external features (i.e.,
facial expressions) of others. Morphed faces representing
five emotions (happiness, sadness, anger, surprise, and
fear) are shown on a screen at six different intensities
(20%, 30%, 40%, 50%, 60%, and 70%) in random order.
Every emotion is shown three times for each level of in-
tensity, resulting in a total of 90 trials. Patients are asked
to name the emotion they see and indicate their level of
confidence in their choice on a 6-point Likert-type scale.
Morphed facial emotion expressions are based on the
NimStim dataset [58]. The dependent measures are ac-
curacy, level of confidence in correct and wrong re-
sponses, and reaction time.
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with the Severity Indices of Personality Problems (SIPP-
118) and the Personality Assessment Inventory-Borderline
(PAI-BOR).
The SIPP-118 [59] is a dimensional self-report meas-
ure assessing the severity of personality pathology. The
SIPP aims to assess the core components of adaptive
and maladaptive personality functioning. It consists of
118 items, and comprises 16 facets that cluster into five
higher-order domains: social concordance, relational
functioning, self-control, responsibility, and identity inte-
gration. The SIPP-118 asks respondents to think about
the past 3 months and to answer with the extent to
which they agree with statements such as “I frequently
say things I regret later” or “Whenever I feel something,
I can almost always name that feeling”. Items are rated
on a 4-point Likert-type scale ranging from 1 (fully dis-
agree) to 4 (fully agree). Higher scores for each facet in-
dicate better functioning. The psychometric features of
the SIPP-118 are good, with evidence for good reliability
(alpha coefficients ranging from .62 to .89, with a mean
estimated α score of .78), convergent validity [59], and
invariance of the factor structure [59].
The Dutch version of the PAI-BOR [60,61] was used
to assess borderline symptomatology. The PAI-BOR is
part of the Personality Assessment Inventory [60] and
consists of four subscales (each with six items), which
reflect four characteristics of BPD: affective instability
(AI), identity problems (IP), negative relationships (NR),
and self-harm (SH). There are four response categories
(0 = false, 1 = slightly true, 2 =mainly true, and 3 = very
true). An example item is “Sometimes I feel very empty
inside”. A total PAI-BOR raw score of 38 or more indicates
the presence of significant BPD features, whereas a score of
60 or more indicates typical borderline personality func-
tioning [60]. The internal consistency (Cronbach’s α) and 6-
month test-retest correlation for both the sum score and
the sub domains are good.
Quality of life Quality of life is measured using the
EuroQol EQ-5D-3 L [62]. This self-report questionnaire
provides a simple method to capture health problems
according to a five-dimensional classification: mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression. Each dimension is divided into three levels:
no problem, moderate problems, and extreme problems.
The five dimensions can be summarized into a “value”,
based on the preferences of the general public. These
values can be used as societal weights for the calculation
of Quality Adjusted Life Years (QALYs) in health eco-
nomic evaluations (see also below). To calculate these
societal weights, we used a Dutch validation study [63].
Adjacent to the five dimensions, the EuroQol presents a
vertical visual analogue scale, ranging from 0 (worstimaginable health) to 100 (best imaginable health), on
which the respondent marks the point that they feel repre-
sents their current health. The values on this scale are
seen as representing patients’ values, in contrary to the so-
cietal weight based on the five dimensions. The reliability
of the EQ-5D-3 L has been investigated and found to be
acceptable [64], and it has shown to be sensitive to change
in patients with personality disorders [14,65].
Social and interpersonal functioning A Dutch transla-
tion of the Inventory of Interpersonal Problems (IIP-64) is
used to assess interpersonal problems [66,67]. The IIP-64
is a self-report measure consisting of 64 items, assessing
eight dimensions of interpersonal problems: (1) domineer-
ing/controlling (sample item: “It is hard for me to take in-
structions from people who have authority over me”), (2)
vindictive/self-centred (“It is hard for me to trust other
people”), (3) cold/distant (“It is hard for me to show affec-
tion to others”), (4) socially inhibited (“It is hard for me to
introduce myself to someone”), (5) non-assertive (“It is
hard for me to be firm when I need to be”), (6) overly ac-
commodating (“It is hard for me to be angry at others”),
(7) self-sacrificing (“It is hard for me to be angry at some-
one I like”), and (8) intrusive/needy (“It is hard for me to
be on my own”). Respondents are asked to consider each
problem and to rate how distressing that problem has
been on a scale ranging from 0 (not at all) to 4 (ex-
tremely). The IIP-64 has shown good psychometric prop-
erties for both the original and the Dutch version [66,67].
DSM-IV Axis I and Axis II diagnoses The Dutch ver-
sion of the SCID-I [41,68] is used to assess Axis I disor-
ders at intake and again at 36-month follow-up. The
interviewer is an MSc-level psychologist, who was trained
by an expert trainer in the SCID-I and SCID-II. The
SCID-I has good interrater reliability (K = .85), especially
when interviewers receive training as in the present study
[69]. The Dutch version of the SCID-II [39,70] is used for
diagnosing Axis II personality disorders at intake and at
36-month follow-up. No interrater reliability data will be
collected in this study. Previous research has shown that
both the original SCID-II and the Dutch version have
good interrater reliability and test–retest interrater reli-
ability in adults [71-73].
Costs The intervention costs of MBT-DH and MBT-
IOP will be calculated using a mixture of top-down and
bottom-up approaches. The intervention costs estimates
will include personnel costs, implementation costs (e.g.,
hosting and coaching), and any other overhead costs as-
sociated with the treatment. Medical costs beyond the
intervention costs specific to MBT-DH and MBT-IOP
will be calculated using the Trimbos and Institute for
Medical Technology Assessment Questionnaire on Costs
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TiC-P will be used to measure health care utilization at
baseline and after 6, 12, 18, 24, and 36 months.
The first part of the TiC-P consists of questions on (1)
the number of visits to, for example, a general practi-
tioner, psychiatrist (outside MBT-DH or MBT-IOP),
medical specialist, physiotherapist or alternative health
practitioner; (2) the day care/hospital lengths of stay
(outside MBT-DH or MBT-IOP); and (3) the use of
medication in the 4 weeks prior to filling out the ques-
tionnaire [74]. These values are multiplied by the unit
prices of the corresponding health care services accord-
ing to the Dutch manual for costing studies in health
care [76,77]. The unit prices will be adjusted to 2014
prices using the Consumer Price Index [78]. As the
mean direct costs are measured per 4 weeks, we will
multiply these values by 13 to obtain estimates for the
annual costs.
The Tic-P also asks the patient to report any product-
ivity losses, that is, absence from work or reduced prod-
uctivity at work. This is used to estimate the so-called
“friction costs”, that is, the monetary representation of
the replacement of the labour. The friction-cost method
takes the employer's perspective and counts as “lost”
only those hours not worked until another employee
takes over the patient's work. This is a more conserva-
tive estimate than the so-called “human capital method”,
which relates productivity costs to the labour costs of
the patient on a one-to-one basis. The choice between
friction costs and human capital is still a subject of de-
bate among economists. In this study, we chose the
more conservative friction-cost method [79,80].
Sample size and power calculation
Sample size calculation is based on the BSI, the primary
clinical outcome variable in this study. We applied the
mixed model ANOVA procedure described by Aberson
[81], power of 0.80 and a two-sided alpha of 0.05.
We anticipated a medium-sized difference in effect
size between MBT-IOP and MBT-DH based on prior
research. In their RCT comparing MBT-IOP with struc-
tured clinical management, Bateman and Fonagy re-
ported a within-group effect size for MBT-IOP of
d =1.31 [29]. In their RCT comparing MBT-DH with
usual care, the same authors reported a within-group ef-
fect size of d = 2.30 for MBT-DH at follow-up [26].
Hence, using an indirect comparison, the previous stud-
ies suggest at least a medium-size difference in effect
(d = 0.50) between both treatment programmes. Apply-
ing seven repeated measures with a linear decrease of
0.5 SD more in MBT-DH than in the MBT-IOP group
and an autoregressive intercorrelation structure with r =
0.50 between baseline and the last follow-up, 45 cases
are needed in each group.Statistical analyses
First, to investigate potential differences between the
two groups at baseline, we will use parametric and non-
parametric descriptive statistics, as appropriate. For the
main analyses concentrating on primary and secondary
outcomes, linear growth curve models for normally dis-
tributed outcome measurements will be used, logistic re-
gression for binary data, and Poisson regression models
for ordinal data. Results will be expressed in terms of
comparison of the slopes for interval data, odds ratios
for binary data, and incidence rate ratios for ordinal
data. Furthermore, we will perform explorative analyses
regarding predictors of differential treatment outcome.
All analyses will be conducted according to intention-to-
treat principles.
Health economic evaluation
We will estimate the difference in total costs for MBT-
DH compared to MBT-IOP and the difference in clinic-
ally relevant effects of the treatments. By dividing the
difference in costs by the difference in effectiveness, the
incremental cost-effectiveness ratio (ICER) will be esti-
mated. The ICER represents the extra amount of money
that has to be invested to gain one extra unit of effect
(or, conversely, the amount of money that will be saved
if one unit of effect is lost).
In the economic evaluation, all relevant costs and ef-
fects will be taken into account. This means that we will
use a so-called societal perspective, which is preferred in
economic evaluations in the Netherlands [82]. The costs
will include all costs, that is, intervention costs, direct
and indirect medical costs, as well as productivity losses
and costs accruing elsewhere in the health care system.
From the societal perspective, clinically relevant effects
are those effects that are meaningful for society. More-
over, in order to be able to compare effects between dif-
ferent interventions in health care, effects should be
expressed in generic terms. We will therefore use QALYs
and will express the cost-effectiveness of each interven-
tion and the ratio between these cost-effectiveness esti-
mates as cost per QALY. The use of QALYs is advised in
guidelines for cost-effectiveness analysis, especially when
main effects are expected in quality of life [82,83].
Our primary cost-effectiveness ratio will be estimated
using empirical data only and therefore a 3-year time
horizon will be used, which is equal to the trial duration.
Cost data are generally highly skewed, and QALY scores
and ICER values are not distributed normally in most
cases. Therefore, the uncertainty intervals around the
mean costs, mean effects and mean ICER values will be
estimated using bootstrap simulations with at least 1000
replications [84-86]. These results will be graphically
presented in a cost-effectiveness plane. Various societal
willingness-to-pay values will be used to estimate net
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used to derive cost-effectiveness acceptability curves.
We will also explore the long-term costs and effects of
MBT-DH and MBT-IOP from a societal perspective. One
way of achieving this would be to use a Markov model to
explore the long-term cost-effectiveness of the interven-
tion under study. However, in a Markov model, health
stages are often predefined, discrete stages, which should
reflect the biological or theoretical understanding of the
condition being modelled [87,88]. Because in this trial the
primary outcome measures, such as the BSI, are continu-
ous measures, it will not be possible to create an unam-
biguous definition of health states to model disease
progression. Using heterogeneous health states may be
controversial, as it means that a wide range of patients
may be clustered in one health state. In order to explore
the cost-effectiveness of the interventions using a Markov
model in our study, we will therefore define health states
on the basis of a cut-off score on one of the outcome mea-
sures such as the BSI, in order to create discrete health
stages. We will extend the cost-effectiveness model results
after the duration of the trial using different assumptions
based on, for example, the literature. Sensitivity analysis
will be performed in order to investigate the influence of
those assumptions on the model results.
Discussion
Both MBT-DH and MBT-IOP have shown promise in
the treatment of patients with BPD [2,15-19]. Yet, extant
studies suggest that MBT-DH may be twice as costly as
MBT-IOP. This cost difference makes MBT-IOP poten-
tially a more cost-effective treatment than MBT-DH. On
this basis, there is a need for an RCT comparing the effi-
cacy and cost-effectiveness of MBT-DH and MBT-IOP.
The present paper outlines the study protocol for such
a head-to-head comparison of MBT-DH and MBT-IOP
in terms of their efficacy and cost-effectiveness in the
context of a multisite study in the Netherlands. The
study aims to answer a number of important questions
in the field. First, this will be the first trial directly com-
paring the efficacy of MBT-DH and MBT-IOP. Second,
this promises to be the first study that entails a state-of-
the-art cost-effectiveness component for both MBT-DH
and MBT-IOP. Given considerable differences in treat-
ment intensity, and thus costs of the two treatment pro-
grammes, the results of this study promise to inform
decisions not only concerning treatment referral, but
also with regard to maximizing the use of health care re-
sources in a climate of decreasing health expenditure.
Another important goal of the final aim of the study,
which focuses on predictors of change, is to provide in-
formation that will contribute to the optimization of
treatment effects and health care resources. For instance,
it may well be that both treatments have equaleffectiveness and differ only in terms of cost. If this were
the case, health care resources should be devoted to the
less costly variant (probably MBT-IOP, due to its lower
intensity). However, even if it is found that both treat-
ments differ only in terms of their costs, there may still
be a subgroup of patients that may need the more inten-
sive intervention, MBT-DH, to derive benefit. In this
scenario, MBT-DH would still be indicated as a cost-
effective treatment in a subgroup of patients, and it
would be crucially important to identify the features of
this subgroup, to enable this intervention to be offered
specifically to the patients who need this more intensive
treatment format. Therefore, this study also aims to
identify potential predictors of response to both MBT-
IOP and MBT-DH, with the aim of facilitating treatment
selection.
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